Europe is emerging as an attractive route to global market access for Chinese sponsors. Early consideration of EMA requirements can help avoid costly delays and improve approval success. Read the article: https://ow.ly...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Harnessing AI and big data in clinical research
The article explores the evolving role of AI and digital technologies in clinical research, highlighting industry trends, adoption challenges, and the potential for improved efficiency, cost reduction, and accelerated drug development.
-
AI, Big Data, and Digital Disruption
This article takes a look at ICON's recent digital disruption survey which surveys changing attitudes and challenges in digital innovation for clinical research.
-
ICON discusses how AI is changing clinical trial recruitment and diversity
Kathleen Mandziuk, Vice President of eClinical Development & Delivery, offers insights on the persistent challenges of patient recruitment, the revolutionary role of AI and digital tools, and the critical importance of diversity and inclusion.
-
AI-powered precision measures: A golden opportunity for clinical research
As the cost of developing new therapies continues to rise, pharma executives must turn to technologies that drive better insights into de-risked investments and produce operational efficiencies. AI-powered digital measures are being developed and validated to better define disease, patients, and drug efficacy.
-
AI’s transformative role in drug discovery and development
In the Irish Times Life Sciences and Stem supplement, ICON’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
-
How AI can manage the risks and costs of postmarketing requirements
Postmarketing requirements (PMRs) for drug development are commonly required to gather data on a product’s longer-term safety, efficacy and optimal use. Carefully applied AI and machine learning offers the potential for better management of PMRs.
-
Us and it
This article by Gerard Quinn, Vice President of IT Innovation and Informatics, which appeared in PharmaTimes Magazine, delves into how AI is transforming clinical trials by improving efficiency, accelerating timelines, and enhancing decisions across the clinical development process.
-
Streamlining bioprocesses with automation
In this article from BioPharm International, Ronan Fox, Senior Vice President, IT R&D, provides commentary on the evolving role of automation in biopharmaceutical development.
-
Human-enabled AI driving enhancements in clinical trial site selection
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
Outsourcing analytical testing: AI could transform analytical labs
In this article from Drug Development & Delivery, Suzanne Jansen, Head of QC Laboratory, discusses the importance of faster data turnaround within the analytical lab to facilitate adaptive dosing decisions that will benefit all stages of clinical trials.
